Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 21 小时前评分70
正文 · 机器翻译
FourLight 数据显示，首款 CDK4i Atirmociclib 在 CDK4/6i 治疗后显著改善 mPFS，9.4 对 6.6 个月，HR=0.60
值得注意的 AE：中性粒细胞减少
#ESMO26 @OncoAlert
184 浏览 · 4 赞 · 4 转发 · 1 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.org帖内回复
- Ziad Storyteller@AIZiadSaliba
@DrSGraff @OncoAlert @antgiorda Slides show the atirmociclib arm carried more liver mets (44% vs 29%) and more ESR1 alterations, yet still delivered HR 0.60. I'd want blinded independent review before calling it, given the investigator-assessed primary endpoint. #ESMO26
来源：Stephanie Graff, MD, FACP, FASCO · x.com